Citations

Clear

2117 citation(s) found for "Mayo, Steven".

SP11. Gene Expressions of Fgf7 and Postn in Canine Chordae Tendineae and Their Possible Relations to Tenogenesis in Chordae Tendineae and Potential Effects on Flexor Tenocyte Biology
Wan, Rou , Ren, Ye , Yu, Yinxian, Reisdorf, Ramona L., Moran, Steven L. , Zhao, Chunfeng , Gingery, Anne

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | July 21, 2023 | Volume: 11 | Issue: 5S | Pages: 126-126

10.1097/01.gox.0000938388.68998.93 Get It

Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250)
Ingham, Matthew , Allred, Jacob B., Chen, Li , Das, Biswasjit , Kochupurakkal, Bose , Gano, Katherine, George, Suzanne , Attia, Steven , Burgess, Melissa , Seetharam, ­Mahesh , Boikos, Sosipatros A. , Bui, Nam Q. , Chen, James L. , Close, Julia , Coté, Gregory M. , D’Andrea, Alan D. , Mariño‐Enríquez, Adrián , Burgess, Melissa A , Bui, Nam , Ivy, S. Percy , Bose, Sminu , D'Andrea, Alan , Marino-Enriquez, Adrian , Shapiro, Geoffrey I , Schwartz, Gary K , George, Suzanne , Ingham, Matthew A , Thaker, Premal H. , Shapiro, Geoffrey I. , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | July 19, 2023 | Volume: 41 | Issue: 25 | Pages: 4154-4163

10.1200/jco.23.00402 | PMID 37467452 Get It

PURPOSE Uterine leiomyosarcoma (uLMS) is an aggressive subtype of soft-tissue sarcoma with frequent metastatic relapse after curative surgery. Chemotherapy provides limited benefit for advanced disease. Multiomics profiling studies have identified homologous recombination deficiency in uLMS. In preclinical studies where olaparib and temozolomide provided modest activity, the combination was highly effective for inhibiting uLMS tumor growth. PATIENTS AND METHODS NCI Protocol 10250 is a single-arm, open-label, multicenter, phase II study evaluating olaparib and temozolomide in advanced uLMS. Patients with progression on ≥1 prior line received temozolomide 75 mg/m2 orally once daily with olaparib 200 mg orally twice a day both on days 1-7 in 21-day cycles. The primary end point was the best objective response rate (ORR) within 6 months. A one-stage binomial design was used. If ≥5 of 22 responded, the treatment would be considered promising (93% power; α = .06). All patients underwent paired biopsies that were evaluated with whole-exome sequencing (WES)/RNAseq and a RAD51 foci formation assay. RESULTS Twenty-two patients were evaluable. The median age was 55 years, and 59% had received three or more prior lines. Best ORR within 6 months was 23% (5 of 22). The overall ORR was 27% (6 of 22). The median progression-free survival (mPFS) was 6.9 months (95% CI, 5.4 months to not estimable). Hematologic toxicity was common (grade 3/4 neutropenia: 75%; thrombocytopenia: 32%) but manageable with dose modification. Five of 16 (31%) of tumors contained a deleterious homologous recombination gene alteration by WES, and 9 of 18 (50%) were homologous recombination-deficient by the RAD51 assay. In an exploratory analysis, mPFS was prolonged for patients with homologous recombination-deficient versus homologous recombination-proficient tumors (11.2 v 5.4 months, P = .05) by RAD51. CONCLUSION Olaparib and temozolomide met the prespecified primary end point and provided meaningful clinical benefit in patients with advanced, pretreated uLMS.
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
Giantonio, Bruce J. , Catalano, Paul J. , Meropol, Neal J. , O’Dwyer, Peter J. , Mitchell, Edith P. , Schwartz, Michael , Benson, Al B. , Schwartz, Michael A , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | July 17, 2023 | Volume: 41 | Issue: 21 | Pages: 3670-3675

10.1200/jco.22.02761 | PMID 37459754 Get It

Purpose Colorectal cancer is the second leading cause of cancer mortality in the United States. Antiangiogenic therapy with bevacizumab combined with chemotherapy improves survival in previously untreated metastatic colorectal cancer. This study was conducted to determine the effect of bevacizumab (at 10 mg/kg) on survival duration for oxaliplatin-based chemotherapy in patients with previously treated metastatic colorectal cancer. Patients and Methods Eight hundred twenty-nine metastatic colorectal cancer patients previously treated with a fluoropyrimidine and irinotecan were randomly assigned to one of three treatment groups: oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) with bevacizumab; FOLFOX4 without bevacizumab; or bevacizumab alone. The primary end point was overall survival, with additional determinations of progression-free survival, response, and toxicity. Results The median duration of survival for the group treated with FOLFOX4 and bevacizumab was 12.9 months compared with 10.8 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for death = 0.75; P = .0011), and 10.2 months for those treated with bevacizumab alone. The median progression-free survival for the group treated with FOLFOX4 in combination with bevacizumab was 7.3 months, compared with 4.7 months for the group treated with FOLFOX4 alone (corresponding hazard ratio for progression = 0.61; P < .0001), and 2.7 months for those treated with bevacizumab alone. The corresponding overall response rates were 22.7%, 8.6%, and 3.3%, respectively ( P < .0001 for FOLFOX4 with bevacizumab v FOLFOX4 comparison). Bevacizumab was associated with hypertension, bleeding, and vomiting. Conclusion The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal cancer.
Multidisciplinary Treatment of Merkel Cell Carcinoma of the Extremities: Outcomes and Factors Associated with Poor Survival in Nodal Disease
Broida, Samuel E. , Chen, Xiao T. , Wahlig, Brian D. , Moran, Steven L. , Houdek, Matthew T. , Houdek, Matthew T , Broida, Samuel E

Mayo Clinic

Current Oncology | June 30, 2023 | Volume: 30 | Issue: 7 | Pages: 6246-6254

10.3390/curroncol30070462 | PMID 37504322 Get It

Merkel cell carcinoma (MCC) has a tendency for lymphatic spread and locoregional recurrence, although there is little data examining the risk factors for patients with lymph node-positive extremity lesions. The purpose of the current study was to examine the outcomes and risk factors associated with nodal metastasis in extremity MCC. We retrospectively reviewed the medical record of 120 patients with extremity MCC evaluated at our institution between 1994 and 2021. The mean age of this cohort was 71 years; 33% of patients were female; and 98% were Caucasian. Seventy-eight (65%) patients presented with localized disease. Thirty-seven (31%) patients had stage III disease, and five (4%) patients had stage IV disease. Treatment of primary lesions consisted primarily of margin-negative excision and adjuvant radiotherapy. Nodal metastases were most treated with adjuvant radiation or completion lymph node dissection. Five-year disease-specific survival in our series was 88% for patients with localized disease, 89% for stage IIIa disease, 40% for stage IIIb disease and 42% for stage IV. Factors associated with worse survival included immunosuppression and macroscopic nodal disease. In conclusion, extremity MCC has a low rate of local recurrence when treated with margin-negative excision and adjuvant radiation. However, treatment of nodal metastases remains a challenge with high rates of recurrence and mortality, particularly for patients who are immunosuppressed or who have macroscopic nodal disease.
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
Goldberg, Richard M. , Morton, Roscoe F., Fuchs, Charles S. , Ramanathan, Ramesh K., Findlay, B., Pitot, Henry C., Williamson, Stephen K. , Findlay, Brian P, Sargent, Daniel J. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | June 28, 2023 | Volume: 41 | Issue: 19 | Pages: 3461-3468

10.1200/jco.22.02759 | PMID 37379691 Get It

PURPOSE Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin. In this study, we compared the activity and toxicity of three different two-drug combinations in patients with metastatic colorectal cancer who had not been treated previously for advanced disease. PATIENTS AND METHODS Patients were concurrently randomly assigned to receive irinotecan and bolus fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus leucovorin (FOLFOX), or irinotecan and oxaliplatin (IROX). The primary end point was time to progression, with secondary end points of response rate, survival time, and toxicity. RESULTS A total of 795 patients were randomly assigned between May 1999 and April 2001. A median time to progression of 8.7 months, response rate of 45%, and median survival time of 19.5 months were observed for FOLFOX. These results were significantly superior to those observed for IFL for all end points (6.9 months, 31%, and 15.0 months, respectively) or for IROX (6.5 months, 35%, and 17.4 months, respectively) for time to progression and response. The FOLFOX regimen had significantly lower rates of severe nausea, vomiting, diarrhea, febrile neutropenia, and dehydration. Sensory neuropathy and neutropenia were more common with the regimens containing oxaliplatin. CONCLUSION The FOLFOX regimen of oxaliplatin and infused fluorouracil plus leucovorin was active and comparatively safe. It should be considered as a standard therapy for patients with advanced colorectal cancer.
Baseline Quality of Life is a Strong and Independent Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer
McGarrah, Patrick W. , Novotny, Paul J. , Sargent, Daniel S., Morton, Roscoe F., Fuchs, Charles S. , Benson, Al B. , Findlay, B., Goldberg, Richard M. , Sloan, Jeff A. , McGarrah, Patrick , Branda, Megan E. , Hubbard, Joleen M. , Sargent, Daniel J. , Williamson, Stephen K. , Alberts, Steven R.

Mayo Clinic

Cancer Control | June 20, 2023 | Volume: 30 | Issue: No issue available | Pages: No page available

10.1177/10732748231185047 | PMID 37339926 Get It

Background Previous studies have established that higher baseline quality of life (QOL) scores are associated with improved survival in patients with metastatic colorectal cancer (mCRC). We examined the relationship between overall survival (OS) and baseline QOL. Patients and Methods A total of 1 247 patients with mCRC participating in N9741 (comparing bolus 5-FU/LV, irinotecan [IFL] vs infusional 5-FU/leucovorin [LV]/oxaliplatin [FOLFOX] vs. irinotecan/oxaliplatin [IROX]) provided data at baseline on overall QOL using a single-item linear analogue self-assessment (LASA) 0–100 point scale. The association of OS according to clinically deficient (defined as CD-QOL, score 0–50) vs not clinically deficient (nCD-QOL, score 51–100) baseline QOL scores was tested. A multivariable analysis using Cox proportional hazards modeling was performed to adjust for the effects of multiple baseline factors. An exploratory analysis was performed evaluating OS according to baseline QOL status among patients who did or did not receive second-line therapy. Results Baseline QOL was a strong predictor of OS for the whole cohort (CD-QOL vs nCD-QOL: 11.2 months vs 18.4 months, P < .0001), and in each arm IFL 12.4 vs 15.1 months, FOLFOX 11.1 months vs 20.6 months, and IROX 8.9 months vs 18.1 months. Baseline QOL was associated with baseline performance status (PS) ( P < .0001). After adjusting for PS and treatment arm, baseline QOL was still associated with OS ( P = .017). Conclusions Baseline QOL is an independent prognostic factor for OS in patients with mCRC. The demonstration that patient-assessed QOL and PS are independent prognostic indicators suggests that these assessments provide important complementary prognostic information.
Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma
Tella, Sri Harsha , Foster, Nathan R. , Shi, Qian , Nguyen, Tran, Chakrabarti, Sakti , Fruth, Briant, Wessling, Jaclynn, Hartgers, Mindy L., Washburn, Leslie, Fernández-Zapico, Martín E. , Hogenson, Tara L. , Pitot, Henry C., Jin, Zhaohui , Mahipal, Amit , Shi, Qian , Wee Ma, Wen, Hartgers, Mindy, Fernandez-Zapico, Martin E , Pitot, Henry, Jin, Zhaohui , Mahipal, Amit , Chakrabarti, Sakti , Borad, Mitesh J. , McWilliams, Robert R. , Alberts, Steven R. , Wee, Wen

Mayo Clinic

The Oncologist | June 20, 2023 | Volume: 28 | Issue: 10 | Pages: 917-e966

10.1093/oncolo/oyad144 | PMID 37339254 Get It

Abstract Background We sought to determine the safety and efficacy of trifluridine/tipiracil in combination with irinotecan in a phase II trial setting for refractory, advanced unresectable biliary tract carcinoma (BTC). Methods A total of 28 patients (27 were evaluable) with advanced BTCs who progressed on at least one prior systemic therapy were enrolled and were treated with trifluridine/tipiracil 25 mg/m2 (days 1-5 of 14-day cycle) and irinotecan 180 mg/m2 (day 1 of the 14-day cycle). The primary endpoint for the study was 16-week progression-free survival (PFS16) rate. Overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and safety were pre-specified secondary endpoints. Results Of 27 patients, PFS16 rate was 37% (10/27; 95% CI: 19%-58%), thereby meeting the criteria for success for the primary endpoint. The median PFS and OS of the entire cohort were 3.9 months (95% CI: 2.5-7.4) and 9.1 months (95% CI: 8.0-14.3), respectively. In the patients evaluable for tumor response (n = 20), the ORR and DCR were 10% and 50%, respectively. Twenty patients (74.1%) had at least one grade 3 or worse adverse event (AE), and 4 patients (14.8%) had grade 4 AEs. A total of 37% (n = 10/27) and 51.9% (n = 14/27) experienced dose reductions in trifluridine/tipiracil and irinotecan, respectively. Delay in therapy was noted in 56% of the patients while 1 patient discontinued the therapy, primarily due to hematologic AEs. Conclusion The combination of trifluridine/tipiracil plus irinotecan is a potential treatment option for patients with advanced, refractory BTCs with good functional status and no targetable mutations. A larger randomized trial is needed to confirm these results. (ClinicalTrials.gov Identifier: NCT04072445)
Radiotherapy toxicity prediction using knowledge-constrained generalized linear model
Hu, Jiuyun, Fatyga, M., Wong, William W. , Vora, Sujay A., Li, Jing , Fatyga, Mirek, Schild, Steven E. , Liu, Wei

Mayo Clinic

IISE Transactions on Healthcare Systems Engineering | June 20, 2023 | Volume: 14 | Issue: 2 | Pages: 130-140

10.1080/24725579.2023.2227199 | PMID 39055377 Get It

Use of the Intercostal Artery-based Latissimus Dorsi Muscle for Intrathoracic Reconstruction after Division of the Thoracodorsal Vessels and Latissimus Dorsi Muscle
Cherukuri, Sai , Bakri, Karim , Moran, Steven L. , Blackmon, Shanda , Mardini, Samir , Gibreel, Waleed

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | June 20, 2023 | Volume: 11 | Issue: 6 | Pages: e5074

10.1097/gox.0000000000005074 | PMID 37456132 Get It

Summary: The latissimus dorsi muscle is the workhorse flap for intrathoracic reconstruction. Prior thoracotomy, which divides the latissimus dorsi muscle, limits the muscle’s intrathoracic reach. We present our experience using the distal portion of the muscle for intrathoracic reconstruction based off an intercostal vessel. We also demonstrate the ability of this intercostal perforator to allow for chimeric flap elevation with a separate skin paddle, depending on the branching pattern of the intercostal vessels. This study provides a case series of three consecutive patients, treated between September 2021 and June 2022. The intrathoracic pathology addressed in these patients are bronchopleural fistula, aortoesophageal fistula, and bronchoesophageal fistula. All patients had the resolution of symptoms related to intrathoracic fistulae and did not experience recurrence. This novel pedicled muscle flap can be an additional option for patients with prior thoracotomy and avoids the morbidity which can be seen with the serratus or rectus abdominis muscle flaps.
The SERPINA5 coding variant E228Q does not contribute to clinicopathologic characteristics in Alzheimer’s disease: A cross-sectional study
Lincoln, Sarah, Baker, Matt , Tamvaka, Nikoleta, Sirmans, Tiffany N. Hicks , Moloney, Christina M. , Helminger, Jacqueline, Hinkle, Kelly M., Cabrera-Rodriguez, Janisse, Wickland, Daniel P. , Reddy, Joseph S. , Younkin, Steven G. , Carrasquillo, Minerva M. , Duara, Ranjan , Graff‐Radford, Neill R. , Pottier, Cyril , Ertekin‐Taner, Nilüfer , Ross, Owen A. , Rademakers, Rosa , Matchett, Billie J. , Lincoln, Sarah J, Labuzan, Sydney A. , Hicks Sirmans, Tiffany N, Murray, Melissa E , Ross, Owen A , Pottier, Cyril , Johnson, Patrick W. , Heckman, Michael G. , Carrasquillo, Minerva M. , Duara, Ranjan , Dickson, Dennis W. , Murray, Melissa E.

Mayo Clinic

Medicine | June 16, 2023 | Volume: 102 | Issue: 24 | Pages: e34017

10.1097/md.0000000000034017 | PMID 37327267 Get It

We previously demonstrated that increased expression of the SERPINA5 gene is associated with hippocampal vulnerability in Alzheimer’s disease (AD) brains. SERPINA5 was further demonstrated to be a novel tau-binding partner that colocalizes within neurofibrillary tangles. Our goal was to determine whether genetic variants in the SERPINA5 gene contributed to clinicopathologic phenotypes in AD. To screen for SERPINA5 variants, we sequenced 103 autopsy-confirmed young-onset AD cases with a positive family history of cognitive decline. To further assess the frequency of a rare missense variant, SERPINA5 p.E228Q, we screened an additional 1114 neuropathologically diagnosed AD cases. To provide neuropathologic context in AD, we immunohistochemically evaluated SERPINA5 and tau in a SERPINA5 p.E228Q variant carrier and a matched noncarrier. In the initial SERPINA5 screen, we observed 1 individual with a rare missense variant (rs140138746) that resulted in an amino acid change (p.E228Q). In our AD validation cohort, we identified an additional 5 carriers of this variant, resulting in an allelic frequency of 0.0021. There was no significant difference between SERPINA5 p.E228Q carriers and noncarriers in terms of demographic or clinicopathologic characteristics. Although not significant, on average SERPINA5 p.E228Q carriers were 5 years younger at age of disease onset than noncarriers (median: 66 [60–73] vs 71 [63–77] years, P = .351). In addition, SERPINA5 p.E228Q carriers exhibited a longer disease duration than noncarriers that approached significance (median: 12 [10–15]) vs 9 [6–12] years, P = .079). More severe neuronal loss was observed in the locus coeruleus, hippocampus, and amygdala of the SERPINA5 p.E228Q carrier compared to noncarrier, although no significant difference in SERPINA5-immunopositive lesions was observed. Throughout the AD brain in either carrier or noncarrier, areas with early pretangle pathology or burnt-out ghost tangle accumulation did not reveal SERPINA5-immunopositive neurons. Mature tangles and newly formed ghost tangles appeared to correspond well with SERPINA5-immunopositive tangle-bearing neurons. SERPINA5 gene expression was previously associated with disease phenotype; however, our findings suggest that SERPINA5 genetic variants may not be a contributing factor to clinicopathologic differences in AD. SERPINA5-immunopositive neurons appear to undergo a pathologic process that corresponded with specific levels of tangle maturity.